pharmaceutical ingredient Articles
-
Artificial Intelligence for New Drug Design
A Technology Platform for Deep-Learning-Based de novo Drug Design Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies. Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, Francebased start-up Iktos is developing a proprietary AI technology for ...
By Iktos
-
Artificial Intelligence for New Drug Design
Iktos Develops a Technology Platform for Deep Learning-Based de novo Drug Development Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies. Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, France-based start-up Iktos is developing a ...
By Iktos
-
Project - Turnkey water system for Aesica Pharmaceuticals
In 2013 Aesica, supplier of Active Pharmaceutical Ingredients (API) and finished dose manufacturing to the pharmaceutical industry, unveiled its new high capacity manufacturing facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults. Puretech supplied the turnkey water system for the facility, including pre-treatment, 3mr/hr Oasys, 10,000 litre ...
-
Evolving Containment in Pharma Manufacturing Facilities
Abstract: Pharmaceutical manufacturing is now undergoing significant transformation. COVID-19 and its pressure on nearly every aspect of human life has put a gigantic emphasis on rapid development of prescriptives, vaccines, and accelerated means for pharmaceutical mass-production. Newer highly potent active pharmaceutical ingredients (HPAPI) hold great promise for the health of the planet, ...
-
A risk based approach to manage active pharmaceutical ingredients in manufacturing effluent
This publication describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools in this publication are not a substitute for compliance with local regulatory requirements, but ...
-
Removal of Active Pharmaceutical Ingredients via Nyex Rosalox
Removal of API’s, EC’s & EDC’s via Nyex Rosalox™ Technology We recently discussed the removal of active pharmaceutical ingredients (API’s) and emerging contaminants (EC’s) in the environment – see Removal of Active Pharmaceutical Ingredients from Water . Endocrine Disrupting Chemicals (EDCs) is another category of compounds whose presence in the ...
By Coftec
-
Chronic toxicity of an environmentally relevant mixture of pharmaceuticals to three aquatic organisms (alga, daphnid, and fish)
Principles of concentration addition (CA) and independent action (IA) have been used as effective tools to predict mixture toxicity based on individual component toxicity. We investigated the toxicity of a pharmaceutical mixture composed of top 10 environmentally detected active pharmaceutical ingredients (APIs) in a relevant concentration ratio. Both individual and mixture toxicities of 10 ...
-
Active pharmaceutical ingredients in wastewater: who are the major contributors?
Active pharmaceutical ingredients (APIs) – responsible for the biological activity of drugs – have been widely found in the environment, yet the precise sources and relative importance of emissions via wastewater are not quite clear. This study assessed emissions from three health institutions in Germany – a hospital, a psychiatric hospital, and a nursing home - and found their ...
-
Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach
Active pharmaceutical ingredient (API) residues have been found to be widespread in the aquatic environment, albeit in most cases at trace levels, with the route to the environment predominantly being via therapeutic use and subsequent excretion to sewer. Although manufacturing discharges may be a low overall contributor to environmental concentrations, they need to be managed effectively so that ...
-
Hoffmann-La Roche - Ozone oxidation for the elimination of active pharmaceutical ingredients from wastewater - Case Study
Hoffmann-La Roche has set up a new facility in Toluca, Mexico for the production of two highly effective cancer treatment drugs. The wastewater generated in this context poses an ecotoxicological risk. Therefore, it needs to be eliminated at the source. Various methods were tested and evaluated from an ecological and economic perspective. According to preliminary studies, the best way to ...
-
Project - Pyrogen free water for the manufacture of vital pharmaceutical ingredients
Project: Commercial Albumin Production Plant Capacity Expansion Client: Albumedix Limited Main Contractor: Scitech UK Duration: May 2019 – November 2020 Puretech designed, manufactured, installed and commissioned a fully validated system for the generation and distribution of essential pyrogen free water to replace the existing legacy system at Albumedix’s facility in ...
-
Selected pharmaceuticals entering an estuary: Concentrations, temporal trends, partitioning, and fluxes
In many coastal watersheds and ecosystems, rivers discharging to estuaries receive waters from domestic wastewater treatment plants resulting in the release and distribution of pharmaceuticals to the marine environment. In the present study, 15 active pharmaceutical ingredients (APIs) were measured regularly over 1 year in the dissolved and particulate phases as they entered Narragansett Bay ...
-
Elimination of active pharmaceutical ingredients (APIs) and other problematic components from wastewater
Pharmaceuticals and their metabolites are detected on an increasing scale in the aquatic environment. The pharmaceuticals (such as drugs) mostly get into the surface and drinking water through the excretions of humans and animals; however, the wastewater of pharmaceutical production facilities can also be contaminated with active ingredients. The production of pharmaceuticals takes place in two ...
-
Fresenius Kabi Oncology Ltd - Case Study
Name: Imran Ahmed Job Title: Senior Research Scientist Company: Fresenius Kabi Oncology Ltd., Gurgoan, India Imran Ahmed, Senior Research Scientist, Fresenius Kabi Oncology Ltd Fresenius Kabi Oncology, performing with Precision Fresenius Kabi Oncology Ltd. primarily operates in the field of research and development, as well as manufacturing, of world-class oncology drugs. The company aims ...
-
Some Basic Facts about Active Pharmaceutical Ingredient Excipients for Drug Discovery
Pharmaceutical excipients are substances formulated together with active pharmaceutical ingredients (APIs) of the drug, and excipients account for most of the drug composition. Excipients are designed to interact with and enhance the properties of APIs. Excipients have various functions. In addition to acting as carriers, and improving stability, pharmaceutical excipients are also conducive in ...
-
Sorption of paracetamol onto biomaterials
Pharmaceutical residues released into the environment are posing more and more public health problems. It is worthwhile to study the retention of pharmaceuticals residues by adsorption on solid supports. Batch sorption experiments are intended to identify the adsorption isotherms of the pharmaceutically active ingredient on the biomaterials. The results obtained in this study have shown that ...
-
Impressive Pump Results - Case Study
When Aurobindo saw the DESMI pumps in another plant in Hyderabad, India, and heard about the easy maintenance and energy savings, they agreed to buy 11 pumps for their plant, too. ”We are very impressed,” says Mr. A. Rajasekhara Reddy when asked about the DESMI pumps and their performance. Mr. Reddy continues, ”The pumps have been in operation for more than a year and we have ...
By DESMI A/S
-
Amorphous Content Determination in Medicine
In industrial production, the surface of the compound may become amorphous due to a small amount of structural damage. It is difficult for conventional instruments to detect this small amount of amorphous substance. Although the content of this amorphous substance is very low, it is very likely to affect the stability of the drug in the production and storage process, resulting in the failure of ...
-
Kex2 Protease from Saccharomyces cerevisiae, Recombinant: A Revolutionary Enzyme in the Biotechnology Industry
Introduction In the world of enzymes, one remarkable protein stands out for its exceptional properties and diverse applications – Kex2 Protease from Saccharomyces cerevisiae, Recombinant. This cutting-edge enzyme has garnered significant attention in the biotechnology industry due to its versatile nature and remarkable catalytic abilities. In this article, we will delve into the world of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you